Pieris Pharmaceuticals (PIRS) Revenue & Revenue Breakdown
Pieris Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$42.81M
Pieris Pharmaceuticals Revenue by Period
Pieris Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $42.81M | 65.28% |
| 2022-12-31 | $25.90M | -17.56% |
| 2021-12-31 | $31.42M | 7.14% |
| 2020-12-31 | $29.32M | -36.64% |
| 2019-12-31 | $46.28M | 59.03% |
| 2018-12-31 | $29.10M | 15.14% |
| 2017-12-31 | $25.27M | 333.48% |
| 2016-12-31 | $5.83M | 98.87% |
| 2015-12-31 | $2.93M | -45.35% |
| 2014-12-31 | $5.37M | -45.70% |
| 2013-12-31 | $9.88M | - |
Pieris Pharmaceuticals generated $42.81M in revenue during NA 2023, up 65.28% compared to the previous quarter, and up 147.11% compared to the same period a year ago.
Pieris Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $53.00K | -95.92% |
| 2023-12-31 | $1.30M | -93.35% |
| 2023-09-30 | $19.52M | -2.67% |
| 2023-06-30 | $20.05M | 935.90% |
| 2023-03-31 | $1.94M | -66.88% |
| 2022-12-31 | $5.85M | 8.86% |
| 2022-09-30 | $5.37M | 45.21% |
| 2022-06-30 | $3.70M | -66.35% |
| 2022-03-31 | $10.99M | 30.14% |
| 2021-12-31 | $8.44M | 108.11% |
| 2021-09-30 | $4.06M | 23.50% |
| 2021-06-30 | $3.29M | -78.99% |
| 2021-03-31 | $15.63M | 732.87% |
| 2020-12-31 | $1.88M | -36.13% |
| 2020-09-30 | $2.94M | -73.87% |
| 2020-06-30 | $11.25M | -15.19% |
| 2020-03-31 | $13.26M | -23.21% |
| 2019-12-31 | $17.27M | 14.13% |
| 2019-09-30 | $15.13M | 183.80% |
| 2019-06-30 | $5.33M | -37.60% |
| 2019-03-31 | $8.54M | 73.89% |
| 2018-12-31 | $4.91M | -41.11% |
| 2018-09-30 | $8.35M | -28.62% |
| 2018-06-30 | $11.69M | 181.58% |
| 2018-03-31 | $4.15M | -77.13% |
| 2017-12-31 | $18.15M | 362.20% |
| 2017-09-30 | $3.93M | 111.95% |
| 2017-06-30 | $1.85M | 37.93% |
| 2017-03-31 | $1.34M | -50.72% |
| 2016-12-31 | $2.73M | 247.22% |
| 2016-09-30 | $785.00K | -26.84% |
| 2016-06-30 | $1.07M | -13.95% |
| 2016-03-31 | $1.25M | 17043.25% |
| 2015-12-31 | $7.27K | -98.21% |
| 2015-09-30 | $407.00K | -166903.28% |
| 2015-06-30 | $-244.00 | -164.38% |
| 2015-03-31 | $379.00 | -99.99% |
| 2014-12-31 | $3.28M | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | - |
Pieris Pharmaceuticals generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Pieris Pharmaceuticals Revenue Breakdown
Pieris Pharmaceuticals Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|
| Customer Revenue | $2.58M | $10.93M | $8.88M |
| Collaboration Revenue | $361.00K | $316.00K | $4.38M |
Pieris Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 20: Customer Revenue (87.72%), and Collaboration Revenue (12.28%).
Pieris Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|
| Collaboration Revenue | $361.00K | $316.00K | $4.38M |
| Customer Revenue | $2.58M | $10.93M | $8.88M |
Pieris Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 20: Customer Revenue (87.72%), and Collaboration Revenue (12.28%).
Pieris Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AGEN | Agenus | $156.31M | $23.51M |
| ADCT | ADC Therapeutics SA | $69.56M | $17.03M |
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| PIRS | Pieris Pharmaceuticals | $42.81M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| AFMD | Affimed | $8.28M | $155.00K |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| CKPT | Checkpoint Therapeutics | $103.00K | $41.00K |
| CRVS | Corvus Pharmaceuticals | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| INZY | Inozyme Pharma | - | - |
| LPTX | Leap Therapeutics | - | - |
| MDNA | Medicenna Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ACHL | Achilles Therapeutics | - | - |
PIRS Revenue FAQ
What is Pieris Pharmaceuticals’s yearly revenue?
Pieris Pharmaceuticals's yearly revenue for 2023 was $42.81M, representing an increase of 65.28% compared to 2022. The company's yearly revenue for 2022 was $25.9M, representing a decrease of -17.56% compared to 2021. PIRS's yearly revenue for 2021 was $31.42M, representing an increase of 7.14% compared to 2020.
What is Pieris Pharmaceuticals’s quarterly revenue?
Pieris Pharmaceuticals's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $53K, a -95.92% decrease from the previous quarter (Q4 2023), and a -97.26% decrease year-over-year (Q1 2023). PIRS's quarterly revenue for Q4 2023 was $1.3M, a -93.35% decrease from the previous quarter (Q3 2023), and a -77.78% decrease year-over-year (Q4 2022).
What is Pieris Pharmaceuticals’s revenue growth rate?
Pieris Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 36.26%, and for the last 5 years (2019-2023) was -7.50%.